# US 2002/0119943 A1 · Novel mammalian gene,bcl-w, belongs to the bcl-2 family of apoptosis-controlling genes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0119943 A1
- Document ID: US20020119943A1
- Status: Published application
- Kind: A1
- Application number: 09/925,674
- Filed: 2001-08-09
- Published: 2002-08-29
- Earliest claimed: 1996-03-27
- Assignees: The Walter and Eliza Hall Institute of Medical Research
- Inventors: Suzanne Cory; Jerry McKee Adams; Leonie M. Gibson; Shaun P. Holmgreen
- Web page: https://patentgrep.com/patent/US20020119943A1

## CPC

- C07K 14/4747: {Apoptosis related proteins}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is broadly directed to therapeutic molecules capable of inter alia modulating apoptosis in mammalian cells. The therapeutic molecules of the present invention encompass genetic sequences and chemical entities capable of regulating expression of a novel mammalian gene belonging to the bcl-2 family and which promotes cell survival. The therapeutic molecules of the present invention may have further utility in delaying cell cycle entry. In addition, the present invention extends to chemical entities capable of modulating activity and function of the translation product of said novel gene of the bcl-2 family. The present invention also extends to the translation product of the novel gene of the bcl-2 family and its use in, for example, therapy, diagnosis, antibody generation and as a screening tool for therapeutic molecules capable of modulating physiological cell death or survival and/or modulating cell cycle entry.

## Claims

### Claim 1

An isolated nucleic acid molecule comprising a nucleotide sequence encoding or complementary to a sequence encoding a novel mammalian gene from the bcl-2 family and comprising an amino acid sequence substantially as set forth in SEQ ID NO:7 or SEQ ID NO:9 or having 47% or greater similarity to either of SEQ ID NO:7 or SEQ ID NO:9.

### Claim 2 (depends on 1)

An isolated nucleic acid molecule according to claim 1 wherein the nucleotide sequence encodes the amino acid sequence set forth in SEQ ID NO:7 or SEQ ID NO:9 or encodes a derivative thereof.

### Claim 3 (depends on 1, 2)

An isolated nucleic acid molecule according to claim 1 or 2 wherein the nucleic acid molecule comprises the nucleotide sequence substantially set forth in SEQ ID NO:6 or SEQ ID NO:8 or comprises a derivative of said sequence.

### Claim 4 (depends on 1, 2)

An isolated nucleic acid molecule according to claim 1 or 2 wherein said nucleic acid molecule is capable of hybridizing to the nucleotide sequence set forth in SEQ ID NO:6 or SEQ ID NO:8 under low stringency conditions and encodes an amino acid sequence which has 47% or greater similarity to the amino acid sequence set forth in SEQ ID NO:7 or SEQ ID NO:9.

### Claim 5

An isolated nucleic acid molecule encoding Bcl-w or a derivative thereof, said nucleic acid molecule selected from the list consisting of:
(i) a nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO:7 or SEQ ID NO:9 or having 47% or greater similarity for SEQ ID NO:7 or SEQ ID NO:9;
(ii) a nucleic acid molecule comprising a nucleotide sequence substantially as set forth in SEQ ID NO:6 or SEQ ID NO:8 or comprising a nucleotide sequence encoding an amino acid sequence 47% or greater similarity to SEQ ID NO:7 or SEQ ID NO:9;
(iii) a nucleic acid molecule capable of hybridizing to the nucleotide sequence substantially set forth in SEQ ID NO:6 or SEQ ID NO:8 under low stringency conditions and encoding an amino acid sequence having 47% or greater similarity to SEQ ID NO:7 or SEQ ID NO:9;
(iv) a nucleic acid molecule capable of hybridizing to the nucleic acid of part (i) or (ii) or (iii) under low stringency conditions and encoding an amino acid sequence having 47% or greater similarity to SEQ ID NO:7 or SEQ ID NO:9; and
(v) a derivative or mammalian homologue of the nucleic acid molecule of parts (i) or (ii) or (iii) or (iv).

### Claim 6

An isolated polypeptide selected from the listing consisting of:
(i) a polypeptide having an amino acid sequence substantially as set forth in SEQ ID NO:7 or SEQ ID NO:9 or a sequence having 47% or greater similarity to SEQ ID NO:7 or SEQ ID NO:9;
(ii) a polypeptide encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:6 or SEQ ID NO:8 or a sequence encoding an amino acid sequence having 47% or greater similarity to SEQ ID NO:7 or SEQ ID NO:9;
(iii) a polypeptide encoded by a nucleic acid molecule capable of hybridizing to the nucleotide sequence set forth in SEQ ID NO:6 or SEQ ID NO:8 under low stringency conditions and which encodes an amino acid sequence substantially as set forth in SEQ ID NO:7 or SEQ ID NO:9 or an amino acid sequence having 47% or greater similarity to SEQ ID NO:7 or SEQ ID NO:9;
(iv) a polypeptide as defined in part (i) or (ii) or (iii) in homodimeric form; and
(v) a polypeptide as defined in part (i) or (ii) or (iii) in heterodimeric form.

### Claim 7 (depends on 6)

An isolated polypeptide according to claim 6 in multimeric form with itself or with another molecule.

### Claim 8 (depends on 7)

An isolated polypeptide according to claim 7 wherein said other molecule is a molecule capable of promoting cell survival and/or delaying cell cycle entry.

### Claim 9 (depends on 7)

An isolated polypeptide according to claim 7 wherein said other molecule is a molecule capable of antagonising cell survival.

### Claim 10 (depends on 7)

An isolated polypeptide according to claim 7 wherein said other molecule is a member of the Bcl-2 family.

### Claim 11

A method for modulating expression of bcl-w or a derivative thereof in a mammal, said method comprising contacting the bcl-w gene with an effective amount of a modulator of bcl-w expression for a time and under conditions sufficient to up-regulate or down-regulate or otherwise modulate expression of bcl-w or its derivative.

### Claim 12 (depends on 11)

A method according to claim 11 wherein the modulator is an antisense molecule to bcl-w or its derivative.

### Claim 13 (depends on 11)

A method according to claim 11 wherein the modulator is a sense molecule regulating expression of Bcl-w or its derivative.

### Claim 14 (depends on 11)

A method according to claim 11 wherein the modulator is a ribozyme capable of targeting bcl-w mRNA.

### Claim 15

A method of modulating activity of Bcl-w or its derivative in a mammal, said method comprising administering to said mammal a modulating effective amount of a molecule for a time and under conditions sufficient to increase or decrease Bcl-w activity.

### Claim 16 (depends on 15)

A method according to claim 15 wherein the molecule is an antibody to Bcl-w or its derivative.

### Claim 17 (depends on 15)

A method according to claim 15 wherein the molecule is a non-membrane form of Bcl-w or is a derivative thereof.

### Claim 18

A pharmaceutical composition comprising Bcl-w or a derivative thereof or a modulator of Bcl-w activity and one or more pharmaceutically acceptable carriers and/or diluents.

### Claim 19 (depends on 6, 7, 8, 9, 10)

An antibody to the polypeptide according to any one of claims 6 to 10.

### Claim 20 (depends on 19)

An antibody according to claim 19 wherein said antibody is a monoclonal antibody.
